Compare VET & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VET | WVE |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | Canada | Singapore |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2004 | 2015 |
| Metric | VET | WVE |
|---|---|---|
| Price | $10.18 | $5.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 16 |
| Target Price | $15.00 | ★ $29.81 |
| AVG Volume (30 Days) | 1.2M | ★ 3.1M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $3.40 | $85.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $7.00 | $5.02 |
| 52 Week High | $14.82 | $21.73 |
| Indicator | VET | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 53.93 | 44.38 |
| Support Level | $9.66 | $5.48 |
| Resistance Level | $10.92 | $6.48 |
| Average True Range (ATR) | 0.32 | 0.30 |
| MACD | 0.17 | -0.02 |
| Stochastic Oscillator | 100.00 | 30.93 |
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe while optimizing low-decline oil assets. Its operating segments are: Canada, France, Netherlands, Germany, Ireland, Australia, and CEE, each representing the oil and gas exploration operations at its assets located in these regions. The company mainly derives revenue from the production and sale of petroleum and natural gas. The majority of its revenue is generated from Canada, where the company's operations are mainly focused on the Deep Basin trend in the West Pembina region of Alberta and on the Mica property.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.